{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02490020",
      "OrgStudyIdInfo": {
        "OrgStudyId": "zssy20150624"
      },
      "Organization": {
        "OrgFullName": "Third Affiliated Hospital, Sun Yat-Sen University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "A Perspective Multicenter Controlled Study On Application Of Mesenchymal Stem Cell(MSC) To Prevent Rejection After Renal Transplantation By Donation After Cardiac Death"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2015",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Enrolling by invitation",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 2016"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2016",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2018",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "June 29, 2015",
      "StudyFirstSubmitQCDate": "July 2, 2015",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 3, 2015",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "July 2, 2015",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 3, 2015",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Qipeng Sun",
        "ResponsiblePartyInvestigatorTitle": "MD",
        "ResponsiblePartyInvestigatorAffiliation": "Third Affiliated Hospital, Sun Yat-Sen University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Qipeng Sun",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Zhujiang Hospital",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Although donation after cardiac death(DCD) is the major source of renal transplantation in China, high incidence rate of rejection and delayed graft function(DGF) is existing due to the prolonged ischemia time. According to the previous single center study, mesenchymal stem cell (MSC) had an effect to prevent rejection and DGF after renal transplantation, but there was no perspective multicenter controlled study to confirm it. This perspective multicenter controlled study will focus on clarifying the key role of MSC applied via renal arterial or peripheral vein injection, to reduce the rejection and DGF after renal transplantation. The investigators have established GMP workshop and solid research foundation of transplant rejection. This study will provide a new reasonable way for immune induction of renal transplantation by DCD."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Disorder Related to Renal Transplantation",
          "Renal Transplant Rejection"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Renal transplantation",
          "mesenchymal stem cell",
          "Transplantation Rejection",
          "donation after cardiac death"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Prevention",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "260",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "iv of BMSC to prevent rejection",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC iv(2*10^6cell/kg, 48h before op)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: mesenchymal stem cell"
              ]
            }
          },
          {
            "ArmGroupLabel": "routine treatment protocol to prevent rejection",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)"
          },
          {
            "ArmGroupLabel": "ia and iv of MSC to prevent rejection",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC (iv 2*10^6cell/kg + ia 5*10^6cell, 48h before op)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: mesenchymal stem cell"
              ]
            }
          },
          {
            "ArmGroupLabel": "routine treatment to prevent rejection",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)"
          },
          {
            "ArmGroupLabel": "Routine CMR treatment plus MSC to prevent CMR",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)+MSC( iv 2*10^6cell/kg at d1,d7)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: mesenchymal stem cell"
              ]
            }
          },
          {
            "ArmGroupLabel": "Routine CMR treatment to prevent CMR",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)"
          },
          {
            "ArmGroupLabel": "Routine AMR treatment plus MSC to prevent AMR",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)+MSC( iv 2*10^6cell/kg at d1,d7)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: mesenchymal stem cell"
              ]
            }
          },
          {
            "ArmGroupLabel": "Routine AMR treatment to prevent AMR",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)"
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "mesenchymal stem cell",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Routine AMR treatment plus MSC to prevent AMR",
                "Routine CMR treatment plus MSC to prevent CMR",
                "ia and iv of MSC to prevent rejection",
                "iv of BMSC to prevent rejection"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Numbers of participants enrolled into the MSC group and control group",
            "PrimaryOutcomeDescription": "80-100 cases will be enrolled to the group.",
            "PrimaryOutcomeTimeFrame": "up to one year"
          },
          {
            "PrimaryOutcomeMeasure": "Incident rates of BPAR and DGF after renal transplantation with MSC prevention before operation",
            "PrimaryOutcomeDescription": "Cases enrolled into the group will be monitored renal function,renal biopsy and other opportunistic infection.The incident rates of DGF and BPAR will be calculated and compare with the control group.",
            "PrimaryOutcomeTimeFrame": "up to one year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nStudy on prevention of MSC to rejection after transplantation\n\nAge between 18-60 years\nhaving the indication of renal transplantation\nhaving no absolute contraindication\nrenal transplantation by donation after citizen death\nthe first time to receive renal transplantation\nsigned informed consent\n\nStudy on treatment of MSC to rejection after transplantation\n\nrenal transplantation by donation after citizen death\nBPAR\nhaving no contraindication of renal biopsy\nsigned informed consent\n\nExclusion Criteria:\n\nloss to follow-up\nserious adverse events",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Qiquan Sun, MD,PhD",
            "OverallOfficialAffiliation": "Third Affiliated Hospital, Sun Yat-Sen University",
            "OverallOfficialRole": "Study Director"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "29514693",
            "ReferenceType": "derived",
            "ReferenceCitation": "Sun Q, Huang Z, Han F, Zhao M, Cao R, Zhao D, Hong L, Na N, Li H, Miao B, Hu J, Meng F, Peng Y, Sun Q. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial. J Transl Med. 2018 Mar 7;16(1):52. doi: 10.1186/s12967-018-1422-x."
          },
          {
            "ReferencePMID": "29145879",
            "ReferenceType": "derived",
            "ReferenceCitation": "Sun Q, Hong L, Huang Z, Na N, Hua X, Peng Y, Zhao M, Cao R, Sun Q. Allogeneic mesenchymal stem cell as induction therapy to prevent both delayed graft function and acute rejection in deceased donor renal transplantation: study protocol for a randomized controlled trial. Trials. 2017 Nov 16;18(1):545. doi: 10.1186/s13063-017-2291-y."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000003643",
            "ConditionMeshTerm": "Death"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M5997",
            "ConditionBrowseLeafName": "Death",
            "ConditionBrowseLeafAsFound": "Cardiac Death",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M3377",
            "InterventionBrowseLeafName": "Antibodies",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9336",
            "InterventionBrowseLeafName": "Immunoglobulins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3382",
            "InterventionBrowseLeafName": "Antibodies, Monoclonal",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}